OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Recent Research in Dementia Care: Costs and Outputs
Submission Deadline: May 30, 2023 (Open) Submit Now
Professor Robert J. Brent, PhD
Department of Economics, Fordham University, Bronx, NY, USA
Research Interests: Cost-Benefit-Analysis; Health Economics; Dementia
About This Topic
From the Public Policy point of view, it is not sufficient just to know that a particular intervention for reducing dementia symptoms has been found to be effective. It is also necessary to know how that intervention compares with other effective interventions that also compete for funds in order that priorities can be set. For this purpose, there needs to be some standardization of research results in terms of the outputs that are produced and the costs of producing those outputs. Towards this objective of standardization, this special issue of the journal invites researchers to submit the results of their existing or new dementia interventions that have outputs and costs expressed in a common way. Outputs are to be expressed in terms of incremental improvements in the Mini-Mental State Examination (MMSE), a relative quick and easy 30-point test of cognitive impairment, which is generally used to record cognitive changes over time. The costs need to be comprehensively measured and therefore include the patients, the caregivers, and the government. The plan is to collect all the individual contributions and rank them to see which interventions deserve the highest priority.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.